Machine learning guides discovery of selective submicromolar CK2 inhibitors
The accepted-paper abstract reports that docking, CDK-liability filtering, machine learning and error prediction guided more selective CK2 inhibitor leads. The authors report submicromolar hits and a 90% pipeline hit rate; kinase-assay figures support biochemical inhibition. These are discovery-stage compounds, with no demonstrated clinical benefit. The hit rate describes the authors' selected pipeline, not a general drug-discovery success rate.
Technology: Machine learning; prediction-error modeling; molecular docking
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Kinase-assay figures report CK2 inhibition by selected hit compounds.
- Still unknown: Full study methods, independent reproduction and clinical outcomes were not assessed.
- AI role: ML and error prediction prioritized compounds after docking and off-target filtering.
Evidence sources: https://www.nature.com/articles/s42004-026-02268-0 · https://www.nature.com/articles/s42004-026-02268-0_reference.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.